These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

923 related items for PubMed ID: 29412838

  • 1. Glucagon-like peptide-1 receptor mediated control of cardiac energy metabolism.
    Al Batran R, Almutairi M, Ussher JR.
    Peptides; 2018 Feb; 100():94-100. PubMed ID: 29412838
    [Abstract] [Full Text] [Related]

  • 2. Glucagon-like peptide-1 receptor action in the vasculature.
    Almutairi M, Al Batran R, Ussher JR.
    Peptides; 2019 Jan; 111():26-32. PubMed ID: 30227157
    [Abstract] [Full Text] [Related]

  • 3. Incretin-mediated control of cardiac energy metabolism.
    Chan JSF, Shafaati T, Ussher JR.
    J Endocrinol; 2024 Oct 01; 263(1):. PubMed ID: 39013412
    [Abstract] [Full Text] [Related]

  • 4. Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors.
    Nauck MA, Meier JJ, Cavender MA, Abd El Aziz M, Drucker DJ.
    Circulation; 2017 Aug 29; 136(9):849-870. PubMed ID: 28847797
    [Abstract] [Full Text] [Related]

  • 5. Immunohistochemical assessment of glucagon-like peptide 1 receptor (GLP-1R) expression in the pancreas of patients with type 2 diabetes.
    Kirk RK, Pyke C, von Herrath MG, Hasselby JP, Pedersen L, Mortensen PG, Knudsen LB, Coppieters K.
    Diabetes Obes Metab; 2017 May 29; 19(5):705-712. PubMed ID: 28094469
    [Abstract] [Full Text] [Related]

  • 6. The GLP-1 Receptor Agonist Liraglutide Increases Myocardial Glucose Oxidation Rates via Indirect Mechanisms and Mitigates Experimental Diabetic Cardiomyopathy.
    Almutairi M, Gopal K, Greenwell AA, Young A, Gill R, Aburasayn H, Al Batran R, Chahade JJ, Gandhi M, Eaton F, Mailloux RJ, Ussher JR.
    Can J Cardiol; 2021 Jan 29; 37(1):140-150. PubMed ID: 32640211
    [Abstract] [Full Text] [Related]

  • 7. Sgemaglutide in type 2 diabetes - is it the best glucagon-like peptide 1 receptor agonist (GLP-1R agonist)?
    Doggrell SA.
    Expert Opin Drug Metab Toxicol; 2018 Mar 29; 14(3):371-377. PubMed ID: 29439603
    [Abstract] [Full Text] [Related]

  • 8. Human epicardial adipose tissue expresses glucose-dependent insulinotropic polypeptide, glucagon, and glucagon-like peptide-1 receptors as potential targets of pleiotropic therapies.
    Malavazos AE, Iacobellis G, Dozio E, Basilico S, Di Vincenzo A, Dubini C, Menicanti L, Vianello E, Meregalli C, Ruocco C, Ragni M, Secchi F, Spagnolo P, Castelvecchio S, Morricone L, Buscemi S, Giordano A, Goldberger JJ, Carruba M, Cinti S, Corsi Romanelli MM, Nisoli E.
    Eur J Prev Cardiol; 2023 Jun 01; 30(8):680-693. PubMed ID: 36799940
    [Abstract] [Full Text] [Related]

  • 9. Glucagon-like Peptide-1 receptor Tie2+ cells are essential for the cardioprotective actions of liraglutide in mice with experimental myocardial infarction.
    McLean BA, Wong CK, Kabir MG, Drucker DJ.
    Mol Metab; 2022 Dec 01; 66():101641. PubMed ID: 36396031
    [Abstract] [Full Text] [Related]

  • 10. The autonomic nervous system and cardiac GLP-1 receptors control heart rate in mice.
    Baggio LL, Ussher JR, McLean BA, Cao X, Kabir MG, Mulvihill EE, Mighiu AS, Zhang H, Ludwig A, Seeley RJ, Heximer SP, Drucker DJ.
    Mol Metab; 2017 Nov 01; 6(11):1339-1349. PubMed ID: 29107282
    [Abstract] [Full Text] [Related]

  • 11. Comparative Analysis of Orthosteric and Allosteric GLP-1R Agonists' Effects on Insulin Secretion from Healthy, Diabetic, and Recovered INS-1E Pancreatic Beta Cells.
    Reed J, Higginbotham V, Bain S, Kanamarlapudi V.
    Int J Mol Sci; 2024 Jun 07; 25(12):. PubMed ID: 38928038
    [Abstract] [Full Text] [Related]

  • 12. Beyond glucose lowering: glucagon-like peptide-1 receptor agonists, body weight and the cardiovascular system.
    Vergès B, Bonnard C, Renard E.
    Diabetes Metab; 2011 Dec 07; 37(6):477-88. PubMed ID: 21871831
    [Abstract] [Full Text] [Related]

  • 13. Targeting GLP-1 receptor trafficking to improve agonist efficacy.
    Jones B, Buenaventura T, Kanda N, Chabosseau P, Owen BM, Scott R, Goldin R, Angkathunyakul N, Corrêa IR, Bosco D, Johnson PR, Piemonti L, Marchetti P, Shapiro AMJ, Cochran BJ, Hanyaloglu AC, Inoue A, Tan T, Rutter GA, Tomas A, Bloom SR.
    Nat Commun; 2018 Apr 23; 9(1):1602. PubMed ID: 29686402
    [Abstract] [Full Text] [Related]

  • 14. Running on mixed fuel-dual agonistic approach of GLP-1 and GCG receptors leads to beneficial impact on body weight and blood glucose control: A comparative study between mice and non-human primates.
    Elvert R, Herling AW, Bossart M, Weiss T, Zhang B, Wenski P, Wandschneider J, Kleutsch S, Butty U, Kannt A, Wagner M, Haack T, Evers A, Dudda A, Lorenz M, Keil S, Larsen PJ.
    Diabetes Obes Metab; 2018 Aug 23; 20(8):1836-1851. PubMed ID: 29938884
    [Abstract] [Full Text] [Related]

  • 15. Impact of GLP-1 and GLP-1 receptor agonists on cardiovascular risk factors in type 2 diabetes.
    Verge D, López X.
    Curr Diabetes Rev; 2010 Jul 23; 6(4):191-200. PubMed ID: 20380625
    [Abstract] [Full Text] [Related]

  • 16. Team Players or Opponents: Coadministration of Selective Glucagon and GLP-1 Receptor Agonists in Obese Diabetic Monkeys.
    Elvert R, Bossart M, Herling AW, Weiss T, Zhang B, Kannt A, Wagner M, Haack T, Evers A, Dudda A, Keil S, Lorenz M, Lorenz K, Riz M, Hennerici W, Larsen PJ.
    Endocrinology; 2018 Aug 01; 159(8):3105-3119. PubMed ID: 29992313
    [Abstract] [Full Text] [Related]

  • 17. Do glucagon-like peptide-1 receptor (GLP-1R) agonists have potential as adjuncts in the treatment of type 1 diabetes?
    Doggrell SA.
    Expert Opin Pharmacother; 2018 Oct 01; 19(15):1655-1661. PubMed ID: 30234389
    [Abstract] [Full Text] [Related]

  • 18. Diabetes and obesity treatment based on dual incretin receptor activation: 'twincretins'.
    Skow MA, Bergmann NC, Knop FK.
    Diabetes Obes Metab; 2016 Sep 01; 18(9):847-54. PubMed ID: 27160961
    [Abstract] [Full Text] [Related]

  • 19. Emerging cardiovascular actions of the incretin hormone glucagon-like peptide-1: potential therapeutic benefits beyond glycaemic control?
    Grieve DJ, Cassidy RS, Green BD.
    Br J Pharmacol; 2009 Aug 01; 157(8):1340-51. PubMed ID: 19681866
    [Abstract] [Full Text] [Related]

  • 20. The Cardiovascular Biology of Glucagon-like Peptide-1.
    Drucker DJ.
    Cell Metab; 2016 Jul 12; 24(1):15-30. PubMed ID: 27345422
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 47.